secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2025-06-10T23:59:59+00:00
Accession:  0001193125-25-138452
Event type: litigation
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Federal Circuit affirms Acadia's NUPLAZID patent validity in MSN litigation
---------------------------------------------------------------------------

- U.S. Court of Appeals affirmed District Court decision confirming validity of Acadia's '740 composition of matter patent for NUPLAZID (pimavanserin).
- Ruling came in patent litigation against MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc.
- Protects Acadia's intellectual property for NUPLAZID, used to treat Parkinson's disease psychosis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312525138452/0001193125-25-138452-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312525138452/d73868d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-138452

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer